Nuclear Medicine Review 2011, tom 14, nr 1

Founded in 1986, IBA mission is to Protect, Enhance and Save  Lives. At IBA, we are a passionate team of professionals dedicated  to developing leading-edge technologies to fight cancer, a disease  that affects us all, either directly or indirectly.With its cyclotrons for PET & SPECT radio-tracers, Synthera  labeling modules and the Integralab concept, IBA provides allthe expertise needed to create your own radio-pharmacy and  produce radiopharmaceuticals for Nuclear Medicine Departments,   thus providing our contribution in the diagnosis of cancer  http://www.iba-molecular.com...

Nuclear medicine and positron emission tomography (PET)  continues to be on the forefront of molecular imaging. In the past  decade, PET imaging established itself as the gold standard for  cancer staging and therapy follow up. To lesser extent, PET is also  used clinically in cardiology (myocardial perfusion) and neurology  (dementia)...

In the last decade, PET/CT (Figure 1) imaging systems have  become an essential tool for staging and restaging various types of  malignant tutors and have been shown to have a significant impact  on patient management. PET/CT also shows exciting potential  in predicting the response to treatment for several types of  cancer, including metastatic breast cancer, lung cancer,  and lymphomas...

July 18–19, 20117th Symposium on Targeted Alpha Therapy2-day symposium on the newest developments in therapywith alpha emitting radionuclidesPalais am FestungsgrabenAm Festungsgraben 110117 Berlin, GERMANY